BACKGROUND: Haemorrhagic cystitis caused by BK virus (BKV) is a known complication of allogeneic haematopoietic cell transplantation (HCT) and is relatively common following HLA-haploidentical transplantation. Adoptive immunotransfer of virus-specific T cells from the donor is a promising therapeutic approach, although production of these cells is challenging, particularly when dealing with low-frequency T cells such as BKV-specific T cells. CASE REPORT: Here, we present a patient who, following haploidentical HCT, developed severe BKV haemorrhagic cystitis, resistant to standard therapy. He responded well to adoptive transfer of donor cells enriched in BKV-specific T cells using the new second-generation CliniMACS Prodigy and the Cytokine Capture System from Miltenyi Biotec. Treatment led to full resolution of both the symptoms and viraemia without unwanted complications. CONCLUSION: Our observations suggest that use of products enriched with BKV-specific T cells generated using this system is safe and efficient in HLA-haploidentical HCT where BKV cystitis can be a serious complication.
BACKGROUND: Haemorrhagic cystitis caused by BK virus (BKV) is a known complication of allogeneic haematopoietic cell transplantation (HCT) and is relatively common following HLA-haploidentical transplantation. Adoptive immunotransfer of virus-specific T cells from the donor is a promising therapeutic approach, although production of these cells is challenging, particularly when dealing with low-frequency T cells such as BKV-specific T cells. CASE REPORT: Here, we present a patient who, following haploidentical HCT, developed severe BKV haemorrhagic cystitis, resistant to standard therapy. He responded well to adoptive transfer of donor cells enriched in BKV-specific T cells using the new second-generation CliniMACS Prodigy and the Cytokine Capture System from Miltenyi Biotec. Treatment led to full resolution of both the symptoms and viraemia without unwanted complications. CONCLUSION: Our observations suggest that use of products enriched with BKV-specific T cells generated using this system is safe and efficient in HLA-haploidentical HCT where BKV cystitis can be a serious complication.
Authors: Benjamin L Laskin; Michelle R Denburg; Susan L Furth; Taylor Moatz; Michelle Altrich; Steve Kleiboeker; Carolyn Lutzko; Xiang Zhu; Jason T Blackard; Sonata Jodele; Adam Lane; Gregory Wallace; Christopher E Dandoy; Kelly Lake; Alexandra Duell; Bridget Litts; Alix E Seif; Timothy Olson; Nancy Bunin; Stella M Davies Journal: Clin Infect Dis Date: 2020-12-15 Impact factor: 9.079
Authors: C Qian; Y Wang; L Reppel; M D'aveni; A Campidelli; V Decot; D Bensoussan Journal: Bone Marrow Transplant Date: 2017-10-23 Impact factor: 5.483
Authors: Dristhi Ragoonanan; Sajad J Khazal; Hisham Abdel-Azim; David McCall; Branko Cuglievan; Francesco Paolo Tambaro; Ali Haider Ahmad; Courtney M Rowan; Cristina Gutierrez; Keri Schadler; Shulin Li; Matteo Di Nardo; Linda Chi; Alison M Gulbis; Basirat Shoberu; Maria E Mireles; Jennifer McArthur; Neena Kapoor; Jeffrey Miller; Julie C Fitzgerald; Priti Tewari; Demetrios Petropoulos; Jonathan B Gill; Christine N Duncan; Leslie E Lehmann; Sangeeta Hingorani; Joseph R Angelo; Rita D Swinford; Marie E Steiner; Fiorela N Hernandez Tejada; Paul L Martin; Jeffery Auletta; Sung Won Choi; Rajinder Bajwa; Natalie Dailey Garnes; Partow Kebriaei; Katayoun Rezvani; William G Wierda; Sattva S Neelapu; Elizabeth J Shpall; Selim Corbacioglu; Kris M Mahadeo Journal: Nat Rev Clin Oncol Date: 2021-02-19 Impact factor: 65.011
Authors: Julia K Bialek-Waldmann; Michael Heuser; Arnold Ganser; Renata Stripecke Journal: Cancer Immunol Immunother Date: 2019-10-18 Impact factor: 6.968